"Fibrinolytic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
| Descriptor ID |
D005343
|
| MeSH Number(s) |
D27.505.519.421.750 D27.505.954.411.320 D27.505.954.502.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolytic Agents".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolytic Agents".
This graph shows the total number of publications written about "Fibrinolytic Agents" by people in this website by year, and whether "Fibrinolytic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 4 | 6 |
| 2013 | 4 | 1 | 5 |
| 2014 | 4 | 2 | 6 |
| 2015 | 5 | 0 | 5 |
| 2016 | 4 | 3 | 7 |
| 2017 | 84 | 31 | 115 |
| 2018 | 79 | 49 | 128 |
| 2019 | 38 | 19 | 57 |
| 2020 | 30 | 19 | 49 |
| 2021 | 10 | 9 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Fibrinolytic Agents" by people in Profiles.
-
Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment. Postgrad Med. 2021 Nov; 133(8):899-911.
-
Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. JCI Insight. 2021 09 08; 6(17).
-
Systemic thrombolysis in ischaemic stroke patients with COVID-19. Acta Neurol Scand. 2022 Jan; 145(1):47-52.
-
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab. Br J Haematol. 2022 01; 196(1):e11-e14.
-
National Trends in Telestroke Utilization in a US Commercial Platform Prior to the COVID-19 Pandemic. J Stroke Cerebrovasc Dis. 2021 Oct; 30(10):106035.
-
The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19. Cardiovasc Res. 2021 07 27; 117(9):e110-e113.
-
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination. Ann Emerg Med. 2021 10; 78(4):511-514.
-
Fibrinolytic Therapy in Patients with Acute ST-elevation Myocardial Infarction. Interv Cardiol Clin. 2021 07; 10(3):381-390.
-
COVID-19 Impact on Acute Ischemic Stroke Treatment at 9 Comprehensive Stroke Centers across Los Angeles. Cerebrovasc Dis. 2021; 50(6):707-714.
-
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis. 2022 Jan; 53(1):96-102.